Blanket Purchase Agreement 36F79721D0141-36E79721A0018

Recordati Rare Diseases Inc. was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs' National Acquisition Center on July 13, 2021, with an ultimate completion date of July 12, 2026. The contract carries a ceiling value of $3.16 million and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) without set-aside designations. This BPA establishes a firm fixed-price procurement vehicle for five specialized orphan pharmaceutical products: Signifor (pasireotide) for treating Cushing's disease and acromegaly, Isturisa (osilodrostat) for managing Cushing's syndrome, Carbaglu (carglumic acid) for hyperammonemia, Cystadane (betaine) for homocystinuria, and Cystadrops (cysteamine) for cystinosis. These medications address uncommon endocrine and metabolic disorders affecting the veteran population and other federal healthcare beneficiaries.

The contract integrates with Recordati's broader Federal Supply Schedule presence and supports the Veterans Integrated Service Networks' capability to access reliable supplies of critical orphan drugs with limited commercial availability. Recordati Rare Diseases Inc., a New Jersey-headquartered subsidiary of the international Recordati Group with manufacturing and distribution operations in Bartlett, Tennessee, functions as the prime contractor with no identified subcontractor involvement. Delivery orders issued under this BPA have been distributed to multiple Veterans Integrated Service Networks, including VISN 5 and VISN 20, which serve regions across Tennessee, Kentucky, the Pacific Northwest, and central New Jersey. The complementary structure of this single-award BPA alongside Recordati's broader multiple-award Federal Supply Schedule contract provides the Department of Veterans Affairs with streamlined procurement flexibility while ensuring continuity of supply for specialized pharmaceutical treatments essential to comprehensive veteran healthcare services.